卵巢癌中CDK10基因启动子甲基化检测的临床意义

Clinical significance of CDK10 gene promoter methylation in ovarian carcinoma

目的:分析卵巢癌中受体O型蛋白酪氨酸磷酸酶(CDK10)基因启动子甲基化状态及临床意义。方法:应用甲基化特异性PCR检测CDK10基因在50例卵巢癌组织和27例正常卵巢组织中的甲基化状态并结合临床病理资料进行分析。结果:在卵巢癌组织中CDK10甲基化阳性率为60.0%(30/50),正常卵巢组织未出现CDK10甲基化;CDK10甲基化与肿瘤临床分期、病理分型与Ki-67表达相关(P<0.05)。结论:CDK10基因甲基化可能是参与卵巢癌发展的重要分子事件。

Objective： To analyze the methylation status of the CDK10 gene promoter in human ovarian carcinoma.Methods： Methylation- specific PCR was performed to observe the CDK10 promoter methyation in 50 cases of ovarian carcinoma tissues companied with 27 cases of normal ovarian tissue. The relationship between CDK10 methyation and clinical pathological parameters was also analyzed. Results： Methylated CDK10 was frequently observed in 60. 0% of primary tumors（ 30 /50）,but not in any normal tissue. CDK10 methylation was significantly correlated with lymphnode metastasis,histological type and Ki- 67 expression status（ P〈0. 05）. Conclusion： CDK10 methylation may be an essential molecular event involved in development of ovarian carcinoma.